Statins Inhibit &bgr;-Adrenergic Receptor–Stimulated Apoptosis in Adult Rat Ventricular Myocytes via a Rac1-Dependent Mechanism

Background—3-Hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) inhibit myocyte hypertrophy in vitro and ameliorate the progression of cardiac remodeling in vivo, possibly because of inhibition of the small GTPase Rac1. The role of Rac1 in mediating myocyte apoptosis is not known. &bgr;-Adrenergic receptor (&bgr;AR)–stimulated myocyte apoptosis is mediated via activation of c-Jun NH2-terminal kinase (JNK), leading to activation of the mitochondrial death pathway. We hypothesized that &bgr;AR-stimulated apoptosis in adult rat ventricular myocyte (ARVMs) is mediated by Rac1 and inhibited by statins. Methods and Results—&bgr;AR stimulation increased apoptosis, as assessed by transferase-mediated nick-end labeling, from 5±1% to 24±2%. &bgr;AR stimulation also increased Rac1 activity. Adenoviral overexpression of a dominant-negative mutant of Rac1 inhibited &bgr;AR-stimulated apoptosis, JNK activation, cytochrome C release, and caspase-3 activation. Cerivastatin likewise inhibited the &bgr;AR-stimulated activation of Rac1, decreased &bgr;AR-stimulated apoptosis to 11±2%, and inhibited JNK activation, cytochrome C release, and caspase-3 activation. Conclusions—&bgr;AR stimulation causes Rac1 activation, which is required for myocyte apoptosis and leads to activation of JNK and the mitochondrial death pathway. Cerivastatin inhibits &bgr;AR-stimulated activation of Rac1 and thereby inhibits JNK-dependent activation of the mitochondrial death pathway and apoptosis. The beneficial effects of statins on the myocardium may be mediated in part via inhibition of Rac1-dependent myocyte apoptosis.

[1]  C. Lim,et al.  Myocyte contractile activity modulates norepinephrine cytotoxicity and survival effects of neuregulin-1beta. , 2004, American journal of physiology. Cell physiology.

[2]  G. Fonarow,et al.  Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. , 2003, Journal of the American College of Cardiology.

[3]  S. Anker,et al.  Statins and the Role of Nitric Oxide in Chronic Heart Failure , 2004, Heart Failure Reviews.

[4]  Steven P Jones,et al.  Simvastatin Attenuates Oxidant-Induced Mitochondrial Dysfunction in Cardiac Myocytes , 2003, Circulation research.

[5]  U. Laufs,et al.  Oxygen Free Radical Release in Human Failing Myocardium Is Associated With Increased Activity of Rac1-GTPase and Represents a Target for Statin Treatment , 2003, Circulation.

[6]  M. Hori,et al.  Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy , 2003, Circulation.

[7]  I. Komuro,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. , 2003, Journal of molecular and cellular cardiology.

[8]  B. Kobilka,et al.  Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. , 2003, The Journal of clinical investigation.

[9]  D. Sawyer,et al.  &bgr;-Adrenergic Receptor–Stimulated Apoptosis in Cardiac Myocytes Is Mediated by Reactive Oxygen Species/c-Jun NH2-Terminal Kinase–Dependent Activation of the Mitochondrial Pathway , 2003, Circulation research.

[10]  U. Ikeda,et al.  Fluvastatin Induces Apoptosis in Rat Neonatal Cardiac Myocytes: A Possible Mechanism of Statin-Attenuated Cardiac Hypertrophy , 2002, Journal of cardiovascular pharmacology.

[11]  A. Curcio,et al.  Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor Simvastatin Prevents Cardiac Hypertrophy Induced by Pressure Overload and Inhibits p21 ras Activation , 2002, Circulation.

[12]  S. Cook,et al.  Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart* , 2002, The Journal of Biological Chemistry.

[13]  R. Gottlieb,et al.  Analyzing mitochondrial changes during apoptosis. , 2002, Methods.

[14]  D. Sawyer,et al.  Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. , 2002, American journal of physiology. Cell physiology.

[15]  P. Kang,et al.  Direct Activation of Mitochondrial Apoptosis Machinery by c-Jun N-terminal Kinase in Adult Cardiac Myocytes* , 2002, The Journal of Biological Chemistry.

[16]  Hiroyuki Tsutsui,et al.  Fluvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction , 2002, Circulation.

[17]  C. Heeschen,et al.  Statins Have Biphasic Effects on Angiogenesis , 2002, Circulation.

[18]  D. Sawyer,et al.  Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. , 2002, American journal of physiology. Cell physiology.

[19]  D. Carling,et al.  Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. , 2002, Diabetes.

[20]  K. Node,et al.  Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. , 2001, The Journal of clinical investigation.

[21]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[22]  D. Sawyer,et al.  Reactive Oxygen Species Mediate Amplitude-Dependent Hypertrophic and Apoptotic Responses to Mechanical Stretch in Cardiac Myocytes , 2001, Circulation research.

[23]  P. Galuppo,et al.  Improvement of Left Ventricular Remodeling and Function by Hydroxymethylglutaryl Coenzyme A Reductase Inhibition With Cerivastatin in Rats With Heart Failure After Myocardial Infarction , 2001, Circulation.

[24]  F. Luft,et al.  Amelioration of Angiotensin II–Induced Cardiac Injury by a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor , 2001, Circulation.

[25]  M. Quiñones,et al.  Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[26]  B. Kobilka,et al.  Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  W. W. Zhang,et al.  Simvastatin inhibits noradrenaline‐induced hypertrophy of cultured neonatal rat cardiomyocytes , 2001, British journal of pharmacology.

[28]  R. Zimlichman,,et al.  Simvastatin Induces Apoptosis of Cultured Rat Cardiomyocytes , 2001, Journal of basic and clinical physiology and pharmacology.

[29]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[30]  E. Lucchinetti,et al.  β-Adrenergic Receptor Subtypes Differentially Affect Apoptosis in Adult Rat Ventricular Myocytes , 2000 .

[31]  T. Hewett,et al.  Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. , 2000, The Journal of clinical investigation.

[32]  R. Kitsis,et al.  Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. , 2000, Circulation.

[33]  E. Lucchinetti,et al.  Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. , 2000, Circulation.

[34]  Catherine Communal,et al.  Opposing Effects of β1- and β2-Adrenergic Receptors on Cardiac Myocyte Apoptosis Role of a Pertussis Toxin–Sensitive G Protein , 1999 .

[35]  S. Sasayama,et al.  α- and β-Adrenergic Pathways Differentially Regulate Cell Type–Specific Apoptosis in Rat Cardiac Myocytes , 1999 .

[36]  ShigetakeSasayama,et al.  α- and β-Adrenergic Pathways Differentially Regulate Cell Type–Specific Apoptosis in Rat Cardiac Myocytes , 1999 .

[37]  J. Kawabe,et al.  Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. , 1999, European journal of pharmacology.

[38]  E. Stein,et al.  Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia. , 1999, The American journal of cardiology.

[39]  Y. Zou,et al.  Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. , 1999, Circulation research.

[40]  D. Sawyer,et al.  Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein. , 1999, Circulation.

[41]  D. Pimentel,et al.  Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. , 1998, Circulation.

[42]  A. Borczuk,et al.  beta-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. , 1998, The American journal of physiology.

[43]  A. Borczuk,et al.  β-Adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. , 1998, American journal of physiology. Heart and circulatory physiology.

[44]  K. Tanaka,et al.  A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. , 1998, The Journal of clinical investigation.

[45]  L. Rubin,et al.  The small GTP-binding protein Cdc42 is required for nerve growth factor withdrawal-induced neuronal death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  O. Faergeman,et al.  The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. , 1997, Journal of cardiac failure.

[47]  M. Karin,et al.  Selective activation of the JNK signaling cascadeand c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs , 1995, Cell.

[48]  P. Crespo,et al.  The small GTP-binding proteins Rac1 and Cdc42regulate the activity of the JNK/SAPK signaling pathway , 1995, Cell.

[49]  E. Lakatta,et al.  Contractile response of individual cardiac myocytes to norepinephrine declines with senescence. , 1992, The American journal of physiology.